What is Zevra Therapeutics, Inc.'s cash ratio?

Zevra Therapeutics, Inc. (ZVRA) reported cash ratio of 2× in Q1 2026.

How has Zevra Therapeutics, Inc.'s cash ratio changed year-over-year?

Zevra Therapeutics, Inc.'s cash ratio increased by 46.9% year-over-year, from 1.4× to 2×.

What is the long-term trend for Zevra Therapeutics, Inc.'s cash ratio?

Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s cash ratio has grown at a 23.2% compound annual growth rate (CAGR), from 0.6× to 1.6×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Zevra Therapeutics, Inc. ZVRA Cash ratio

Cash ratio at other companies

BioMarin PharmaceuticalsBMRN

3.9×+2.2×

Ultragenyx PharmaceuticalRARE

0.5×+0.1×

XER

Xeris Biopharma Holdings, Inc.XERS

0.9×+0.3×

Eton Pharmaceuticals, Inc.ETON

0.4×-0.2×

Theravance BiopharmaTBPH

9.1×+5.6×

Relay Therapeutics, Inc.RLAY

6.9×+4.4×

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+56.4%

Enterprise value$678.78M+30.8%

P/E6.2×—

P/S6.3×-5.9×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Calculated from Zevra Therapeutics, Inc.’s reported figures.

cash and equivalents/total current liabilities=2×

Based on the most recent quarter.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s cash ratio?: Zevra Therapeutics, Inc. (ZVRA) reported cash ratio of 2× in Q1 2026.
How has Zevra Therapeutics, Inc.'s cash ratio changed year-over-year?: Zevra Therapeutics, Inc.'s cash ratio increased by 46.9% year-over-year, from 1.4× to 2×.
What is the long-term trend for Zevra Therapeutics, Inc.'s cash ratio?: Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s cash ratio has grown at a 23.2% compound annual growth rate (CAGR), from 0.6× to 1.6×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.